Drug intelligence / Profile preview

Asia Anti-Snake Antivenom

Development stage: Unknown
Lead developer: Inosan Biopharma
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

Asia Anti-Snake Antivenom is a polyvalent antivenom candidate being developed by Inosan Biopharma for the treatment of snake envenomation in Asia. The therapeutic consists of equine-derived F(ab')2 immunoglobulin fragments designed to neutralize a broad spectrum of snake venom toxins. By binding to these toxins, the antivenom prevents them from interacting with their physiological targets, thereby mitigating the systemic and local effects of envenomation. The product is currently in Phase 1 clinical development.

Other names: Asia Anti-Snake Antivenom

Beyond the preview

Go deeper on Asia Anti-Snake Antivenom.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asia Anti-Snake Antivenom.

Explore the full profile